IL266279B2 - Aqueous formulations, stability of pexacin for injection and medical uses thereof - Google Patents

Aqueous formulations, stability of pexacin for injection and medical uses thereof

Info

Publication number
IL266279B2
IL266279B2 IL266279A IL26627919A IL266279B2 IL 266279 B2 IL266279 B2 IL 266279B2 IL 266279 A IL266279 A IL 266279A IL 26627919 A IL26627919 A IL 26627919A IL 266279 B2 IL266279 B2 IL 266279B2
Authority
IL
Israel
Prior art keywords
formulation
capsaicin
certain embodiments
mol
pain
Prior art date
Application number
IL266279A
Other languages
English (en)
Hebrew (he)
Other versions
IL266279A (en
IL266279B1 (en
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of IL266279A publication Critical patent/IL266279A/en
Publication of IL266279B1 publication Critical patent/IL266279B1/en
Publication of IL266279B2 publication Critical patent/IL266279B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL266279A 2016-11-02 2019-04-28 Aqueous formulations, stability of pexacin for injection and medical uses thereof IL266279B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416345P 2016-11-02 2016-11-02
PCT/US2017/059628 WO2018085476A1 (en) 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof

Publications (3)

Publication Number Publication Date
IL266279A IL266279A (en) 2019-06-30
IL266279B1 IL266279B1 (en) 2023-03-01
IL266279B2 true IL266279B2 (en) 2023-07-01

Family

ID=62077165

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266279A IL266279B2 (en) 2016-11-02 2019-04-28 Aqueous formulations, stability of pexacin for injection and medical uses thereof

Country Status (11)

Country Link
US (7) US11000490B2 (https=)
EP (1) EP3534961B1 (https=)
JP (1) JP7100635B2 (https=)
KR (1) KR102657458B1 (https=)
CN (1) CN110035740B (https=)
AU (1) AU2017353782B2 (https=)
CA (1) CA3041121A1 (https=)
IL (1) IL266279B2 (https=)
MX (1) MX2019005202A (https=)
NZ (1) NZ752750A (https=)
WO (1) WO2018085476A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102657458B1 (ko) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
KR20210151949A (ko) 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
TR2021013305A2 (tr) * 2021-08-23 2023-03-21 Tuem Ekip Ilac Anonim Sirketi Li̇yofi̇li̇ze levosi̇mendan formülasyonlari

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075084A2 (en) * 2012-11-12 2014-05-15 Api Genesis Llc Aqueous based capsaicinoid formulations and methods of manufacture and use

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE219674T1 (de) 1997-03-13 2002-07-15 James N Campbell Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
EP0984781A1 (en) 1997-05-27 2000-03-15 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
JP2005538983A (ja) 2002-07-19 2005-12-22 メステックス アクチエンゲゼルシャフト 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法
PT1605956E (pt) 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
US20040156931A1 (en) 2002-12-18 2004-08-12 Algorx Administration of capsaicinoids
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
RU2373953C2 (ru) 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
DE502004011941D1 (de) 2004-12-22 2011-01-05 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
ES2533256T3 (es) 2004-12-28 2015-04-08 Mestex Ag Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor
EP1830835B1 (de) 2004-12-28 2012-03-14 Mestex AG Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8222564B2 (en) 2008-02-13 2012-07-17 Tyco Healthcare Group, Lp Methods of altering surgical fiber
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
JP6002385B2 (ja) 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
TW201302681A (zh) 2011-03-25 2013-01-16 Abbott Lab Ｔｒｐｖ１拮抗劑
EP3388057B1 (en) 2011-09-09 2022-03-09 Propella Therapeutics, Inc. A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
CA2868416A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release pharmaceutical compositions with abuse deterrent properties
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
JP2015523401A (ja) 2012-08-03 2015-08-13 メステックス・アー・ゲー レシニフェラトキシン溶液
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
JP6487452B2 (ja) 2014-01-24 2019-03-20 センティス ファーマ プライベート リミテッド ブリンゾラミドを含む医薬組成物
US20170042834A1 (en) 2014-04-14 2017-02-16 Flex Pharma, Inc. Ion channel activators and methods of use
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
MX377377B (es) 2014-04-15 2025-03-10 Propella Therapeutics Inc Composiciones tópicas para el alivio del dolor, manufactura y uso.
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
KR20170066344A (ko) 2014-08-19 2017-06-14 만디쇼라 이스라엘 무자리 약제로서의 캡시노이드 및 그의 용도
JP2017534656A (ja) 2014-11-13 2017-11-24 セントレクシオン セラピューティクス コーポレイション 肢端舐性肉芽腫の治療に使用するためのカプサイシノイド
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2016126540A1 (en) 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US9989978B2 (en) 2016-01-21 2018-06-05 Itt Manufacturing Enterprises Llc Natural gas pressure regulator having adjustable valve seat
EP3405187A4 (en) 2016-01-22 2019-07-31 Centrexion Therapeutics Corporation SEQUENCING DOSAGE METHOD FOR CAPSAICN FOR THE TREATMENT OF MORTON NEUROM
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
KR102657458B1 (ko) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075084A2 (en) * 2012-11-12 2014-05-15 Api Genesis Llc Aqueous based capsaicinoid formulations and methods of manufacture and use

Also Published As

Publication number Publication date
JP7100635B2 (ja) 2022-07-13
US20210052522A1 (en) 2021-02-25
AU2017353782B2 (en) 2022-06-02
CA3041121A1 (en) 2018-05-11
EP3534961B1 (en) 2026-02-11
US20240423931A1 (en) 2024-12-26
EP3534961C0 (en) 2026-02-11
NZ752750A (en) 2023-05-26
MX2019005202A (es) 2019-10-14
KR102657458B1 (ko) 2024-04-12
JP2019537589A (ja) 2019-12-26
EP3534961A1 (en) 2019-09-11
US11344516B2 (en) 2022-05-31
US20220211649A1 (en) 2022-07-07
EP3534961A4 (en) 2020-05-27
IL266279A (en) 2019-06-30
CN110035740A (zh) 2019-07-19
IL266279B1 (en) 2023-03-01
US10772853B2 (en) 2020-09-15
US11000490B2 (en) 2021-05-11
US20200093766A1 (en) 2020-03-26
US20190254996A1 (en) 2019-08-22
US20200046656A1 (en) 2020-02-13
WO2018085476A1 (en) 2018-05-11
AU2017353782A1 (en) 2019-05-16
RU2019116788A3 (https=) 2021-02-25
US10493047B2 (en) 2019-12-03
KR20190101368A (ko) 2019-08-30
BR112019008239A2 (pt) 2019-07-16
US20200093765A1 (en) 2020-03-26
US11992470B2 (en) 2024-05-28
CN110035740B (zh) 2023-08-04
US10765649B2 (en) 2020-09-08
RU2019116788A (ru) 2020-12-03

Similar Documents

Publication Publication Date Title
IL266279B2 (en) Aqueous formulations, stability of pexacin for injection and medical uses thereof
AU2013341380B2 (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
EP3068373B1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
AU2018302342B2 (en) Methods and compositions for treatment of pain using capsaicin
IE58130B1 (en) Pharmaceutical compositions and method for preparing phosphatidylserine compositions useful in treating central nervous system disorders without effects on blood coagulation
CN102481313A (zh) 抑制疼痛的药物组合物
US20240216348A1 (en) Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
RU2779862C2 (ru) Стабильные водные инъекционные составы капсаицина и их медицинские применения
AU2019325407B2 (en) Capsaicin sequential dosing method for treatment of knee joint pain
BR112019008239B1 (pt) Formulações aquosas, estáveis, injetáveis, de capsaicina e usos médicos das mesmas